# Cysal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cysal

- Industry: Biotechnology
- Headquarters: Munster, Germany
- Website: www.cysal.de
- Latest round: Seed (Nov 8, 2012)
- Investors on record: 2

## About

Cysal GmbH is a biotechnology company focused on advanced biotechnological fermentation strategies, replacing traditional chemical processes for the production of specialty and base commodities.Founded in 2012 in Munster, Germany, Cysal GmbH operates within the biotechnology sector, providing specialized fermentation technologies. The company has not undergone significant pivots or changes in its business strategy since its inception. It was established by a group of individuals with expertise in the field, though specific founder details are not available. Cysal has secured Seed funding in November 2012 from eCAPITAL entrepreneurial Partners AG’s Gründerfonds Münsterland and High-Tech Gründerfonds II. The company has completed one deal to date, with the most recent deal occurring in November 2012.Cysal GmbH specializes in advanced biotechnological fermentation strategies that replace traditional chemical methods for producing specialty and base commodities. Their core offerings include the optimization and selection of microbial strains tailored for the production of new compounds and activities, alongside the development of complete fermentation and downstream technologies scalable to industrial levels. Cysal’s services cater to various sectors, specifically targeting biotechnology companies, including science-to-business startups, by providing flexible and affordable solutions for developing novel industrial fermentation technologies. These innovations are designed to address increasing market demands for sustainable alternatives in cosmetics, food, and feed applications. Cysal operates within a well-connected network of German and international collaborators, extending its reach to diverse geographical markets across Europe, North America, and Asia.Cysal GmbH generates revenue through a variety of business transaction structures primarily involving partnerships, consultancy services, and project-based contracts. The company engages in direct collaborations with biotechnology firms and startups, offering hands-on support in areas such as intellectual property, feasibility studies, and regulatory affairs. This business model typically includes project fees for the development of tailored fermentation processes and microbial strain optimizations, allowing clients to scale their production efficiently. Cysal's revenue streams are further bolstered through licensing agreements, particularly involving patented technologies related to functional ingredients. The company’s focus on delivering sustainable biotechnological solutions positions it favorably within a market increasingly oriented towards environmentally friendly industrial practices.Cysal GmbH is focused on expanding its product offerings and market presence. The company aims to design and launch new fermentation technologies targeting the cosmetics and food sectors by 2024. Plans are in place to expand into North American markets, particularly the United States, by 2025. The Seed funding received in November 2012 will be utilized to support these initiatives, enabling Cysal to enhance its technological capabilities and market reach.

## Funding rounds

- Seed, Nov 8, 2012 — eCAPITAL, High-Tech Gruenderfonds

## Investors

- eCAPITAL (https://capitalatlas.ai/funds/ecapital) — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed